Sirnaomics, a biopharmaceutical company involved in discovery and development of RNAi therapeutics, appointed Francois Lebel senior vice president for preclinical and clinical development of the group. Lebel will take a leading role in the group’s late-stage product development of the innovative RNAi drug candidates. Lebel has broad drug development experience including immunooncology and nucleic acid therapeutics. Throughout his 30-year biopharma career at companies including GSK, Pfiz...